Phenols, including phenol and p-cresol, are aromatic compounds that result from the microbial fermentation of aromatic amino acids, such as tryptophan and tyrosine. These compounds are cytotoxic and may cause damage to the gut, skin, vascular system, kidneys, and more. Tyrosine tends to be metabolized to phenol by Escherichia coli, Proteus spp., and Streptococcus faecalis, whereas it tends to be metabolized to p-cresol by strictly anaerobic gut bacteria such as Bacteroides fragilis, Fusobacterium spp., and Clostridium spp. Tryptophan is abundant in foods such as cheese, poultry, red meat, egg whites, and seeds; and therefore, these foods can increase phenol production in the gut. Similarly, tyrosine is also present in protein-rich foods including beef, pork, chicken, fish, chicken, tofu, milk, cheese, beans, seeds, nuts, and whole grains. When paired with a diet low in fermentable fibers, these foods have the potential to dramatically increase phenol and p-cresol production, as gut microbes are forced to use amino acids for energy. Increasing gut acidity through the intake of resistant starches, galactooligosaccharides, and fructooligosaccharides may reduce the production of these toxic metabolites.

P-Ethanolamine, Plasma is short for Phosphoethanolamine (PEA). Phosphoethanolamine (PEA) is a marker measured in the plasma as part of an Amino Acid Profile, Quantitative (Qn) panel. This compound is a derivative of the amino acid serine and plays a critical role in the biosynthesis of phospholipids, which are essential components of cell membranes. In the body, PEA serves as a precursor to phosphatidylethanolamine, one of the most abundant phospholipids in cell membranes, and is involved in various cellular processes, including membrane signaling and repair. Elevated levels of phosphoethanolamine in the plasma can indicate metabolic disruptions or inherited metabolic disorders such as phosphoethanolaminuria, where there is an abnormal accumulation of PEA due to enzyme deficiencies. These elevations may be associated with a range of clinical symptoms, including neurological abnormalities, developmental delays, and muscle weakness. Therefore, measuring phosphoethanolamine levels helps clinicians diagnose and monitor metabolic disorders, guiding appropriate treatment and management strategies. Conversely, normal levels of PEA suggest that the phospholipid metabolism pathway is functioning properly, which is an essential aspect of maintaining cellular integrity and function.

P-Ethanolamine stands for Phosphoethanolamine. Phosphoethanolamine is a compound involved in the metabolism of phospholipids, which are essential components of cell membranes. Elevated levels of phosphoethanolamine in urine can indicate metabolic disorders or conditions related to phospholipid metabolism. For instance, abnormal levels may be associated with certain types of metabolic diseases, vitamin B6 deficiency, or issues with kidney function. Monitoring phosphoethanolamine levels can help healthcare providers diagnose these conditions, assess the effectiveness of treatments, and understand more about a patient's metabolic health. It's an important marker because it provides information that can lead to early detection and management of metabolic abnormalities, ultimately contributing to better health outcomes.

p100
Serum

P100 Biomarker in Borrelia Test Panel: Understanding Its Role in Lyme Disease Diagnosis When it comes to diagnosing Lyme disease, a condition caused by the Borrelia burgdorferi bacteria, healthcare providers often rely on a combination of clinical evaluation, patient symptoms, and specific laboratory tests. One of the components sometimes found on a Borrelia test panel is the P100 biomarker. Understanding what this biomarker signifies and how it fits into Lyme disease diagnostics can shed light on the often-complex process of diagnosing this tick-borne illness. What is the P100 Biomarker? P100 is a protein antigen found in the Borrelia burgdorferi bacterium. This protein, along with others like P41, OspC, and others, is used to detect the presence of an immune response to Lyme disease. The P100 antigen, sometimes referred to as the 100 kDa protein, gets its name from its molecular weight. This protein becomes relevant in Lyme disease testing because it is associated with the immune response to the infection; when the immune system encounters Borrelia burgdorferi, it generates antibodies that specifically target bacterial antigens, including P100. Detecting antibodies against P100 can provide insight into a patient’s exposure to the Lyme-causing bacteria. The Role of P100 in Lyme Disease Diagnosis Lyme disease testing usually follows a two-tiered approach, with an initial ELISA (enzyme-linked immunosorbent assay) screen followed by a confirmatory Western blot test if the ELISA is positive or indeterminate. The Western blot test breaks down the analysis of a patient’s immune response by examining reactivity against specific Borrelia proteins—this is where P100 can be especially valuable. In Western blot testing, the P100 band, among other bands, is observed to determine whether specific antibodies are present. The appearance of the P100 band generally indicates an immune response against Borrelia burgdorferi. However, it’s important to note that no single protein band alone is definitive for diagnosing Lyme disease; instead, a combination of several bands, including P100, contributes to a more complete picture of whether Lyme disease is likely. The CDC (Centers for Disease Control and Prevention) typically recommends that IgG Western blot positivity requires reactivity on at least 5 of 10 specified bands, while IgM positivity requires at least 2 of 3 bands, though the inclusion of the P100 band varies by testing standards and clinical guidelines. Why is P100 Significant? The P100 biomarker is often considered significant in long-term or chronic cases of Lyme disease. Studies suggest that while some of the other Borrelia proteins, like P41 (flagellin) or OspC, may be detected early in infection, P100 may not be detectable until later stages. Its presence is, therefore, more often associated with a prolonged immune response. When P100 reactivity is present, it could suggest that the patient has had an infection for an extended period, or it might reflect ongoing immune activation, even after initial infection. Due to this potential association with late-stage or chronic infection, some practitioners view the P100 band as relevant for patients with persistent symptoms who may have missed an early Lyme diagnosis. However, more research is needed to fully understand the timing of P100 appearance and its clinical significance across different stages of Lyme disease. Limitations and Considerations of P100 in Lyme Testing While the detection of P100 can contribute valuable information, there are limitations to using it, and it should not be used in isolation. Lyme disease is known for its complex presentation and varied immune response, meaning that some patients with Lyme disease may not produce detectable antibodies against P100 or may not develop detectable immune responses to certain Borrelia proteins. False positives can also occur due to cross-reactivity with antibodies from other infections. Moreover, antibody-based tests have inherent limitations because antibodies can persist even after the infection is cleared, leading to potential false-positive results in those who were infected in the past but are not currently symptomatic. P100, like other Borrelia-specific antigens, can contribute to this complexity since its detection doesn’t always correlate with active infection. P100 and Immune System Response From an immunological perspective, P100’s role reflects the body’s adaptive immune response, which is specific and tends to develop over time. When Borrelia burgdorferi infects the body, it initially triggers the innate immune response. If the bacteria persist, the adaptive immune system ramps up, creating specific antibodies against unique Borrelia proteins like P100. However, as Borrelia can evade immune detection through various mechanisms, such as altering its surface proteins, the immune response can be inconsistent and may vary greatly from one person to another. For some patients, especially those with ongoing symptoms that resemble post-treatment Lyme disease syndrome (PTLDS), detecting antibodies to proteins like P100 could potentially provide evidence of an enduring immune response. Yet, the direct relationship between these antibodies and persistent symptoms is still an area of active research, with ongoing debates about how best to interpret late-stage antibody responses in clinical practice. Interpretation of P100 in the Clinical Context While detecting antibodies against P100 can indicate a Borrelia infection, it’s important to interpret this result within the broader clinical context. Symptoms, history of tick exposure, and timing of test results all influence the diagnostic process. In cases of chronic or late-stage Lyme disease, if P100 is reactive along with other relevant Borrelia proteins, this may support the diagnosis, but it is not definitive on its own. Other diagnostic tools, including PCR or newer methods focusing on active infection detection, may be employed to complement antibody testing and provide a clearer view of a patient’s status. When a P100 result is positive but both Borrelia Western Blot IgG and IgM results are negative, it presents a complex diagnostic scenario. The presence of P100 could suggest that the immune system has encountered Borrelia burgdorferi, the bacteria responsible for Lyme disease, especially if the patient has a history of symptoms that align with Lyme. However, the lack of IgG and IgM reactivity, which are primary markers used to confirm active or past infection, complicates interpretation, as these antibodies generally validate a Lyme diagnosis. A positive P100 in this context might indicate a past exposure or interaction with Borrelia burgdorferi that did not lead to a conventional IgM or IgG antibody response, possibly due to variations in individual immune responses or timing of testing relative to infection. This nuanced result typically warrants further investigation. A healthcare provider may consider additional testing methods, such as PCR for Borrelia DNA, which detects the bacteria directly rather than relying on antibody responses. PCR can be especially helpful if there's suspicion of an active infection. Repeating the Western Blot test after a few weeks could also reveal changes in antibody levels, as some individuals may develop detectable IgG or IgM antibodies over time. If symptoms are ongoing or consistent with Lyme disease, retesting or considering other Lyme-related serology tests could provide further insights. Testing for other tick-borne diseases (e.g., Babesia, Ehrlichia) may also be beneficial, as co-infections can mimic Lyme symptoms and complicate diagnosis. In summary, a positive P100 without IgM or IgG reactivity requires a careful and thorough approach, including clinical evaluation, follow-up testing, and consideration of other possible causes. This comprehensive assessment can help determine if Lyme disease or another condition is likely contributing to the patient’s symptoms. Conclusion P100 is one of many important biomarkers on the Borrelia test panel, contributing to the complex diagnostic landscape of Lyme disease. It reflects the body’s immune response to Borrelia burgdorferi, particularly in cases where the infection might have persisted over time. While it can be an indicator of past or chronic infection, it’s not definitive in isolation. Instead, P100 reactivity should be interpreted with caution and in conjunction with other clinical findings and laboratory results. The continued study of biomarkers like P100 is essential in enhancing our understanding of Lyme disease, improving diagnostic accuracy, and ultimately aiding in the effective management of this challenging condition.

The Epstein-Barr Virus (EBV) p18 IgG marker is a vital component of the NeuralZoomer Plus panel from Vibrant Wellness, designed to assess neurological health and the risk of autoimmunity. EBV, a widespread herpesvirus, infects most people at some point in their lives, potentially leading to infectious mononucleosis. However, many individuals carry the virus asymptomatically. The p18 IgG marker specifically indicates the body's immune response to EBV, focusing on the production of Immunoglobulin G (IgG) antibodies against the virus's p18 protein—a component of the viral capsid antigen (VCA), essential for the virus's infection and replication processes. The presence of IgG antibodies against EBV's p18 suggests a past or chronic infection, offering significant insights into a patient's immune system status and potential neurological or autoimmune disease risk factors. This testing is crucial, as chronic EBV infection is linked to various neurological conditions and autoimmune diseases. The NeuralZoomer Plus panel facilitates early detection and intervention, providing a personalized approach to prevent and manage neurological health issues. By including the EBV p18 marker, the panel offers a comprehensive view of the body's immune activity against EBV, essential for diagnosing and treating conditions with a potential viral cause.

Epstein-Barr Virus p23 (EBV-p23) IgG – What Your Test Result Means What is Epstein-Barr Virus p23? The Epstein-Barr Virus p23 (EBV-p23) marker detects IgG antibodies targeting a specific early antigen (EA-D) protein of the Epstein-Barr Virus (EBV)—a common herpesvirus that infects over 90% of people worldwide. The p23 protein is part of the early antigen complex, which appears during active viral replication. IgG antibodies to p23 suggest that your immune system recognizes and has responded to this specific EBV protein. What Does an Elevated EBV-p23 IgG Mean? Elevated IgG to EBV-p23 may indicate: A recent or reactivated EBV infection, or Ongoing immune system activation in response to latent virus Since p23 is part of the early antigen complex, reactivity may reflect: Viral reactivation under stress or immune suppression Possible contribution to chronic fatigue, autoimmune activity, or neurological symptoms This is particularly important on panels like Neural Zoomer Plus, which look for infections or immune responses that may affect brain and nerve function. EBV Reactivation and Health Impacts While most people carry EBV in a dormant state, reactivation can occur—sometimes without symptoms, and other times with effects such as: Fatigue or brain fog Chronic inflammation Flare-ups in autoimmune conditions (e.g., lupus, MS) Neurological or psychiatric symptoms (in rare cases) Clinical Relevance of EBV-p23 IgG This marker alone does not diagnose a disease, but a positive or elevated result may be meaningful when: You have symptoms like fatigue, cognitive decline, or autoimmunity Multiple EBV antibodies are elevated (e.g., VCA IgG, EBNA IgG, EA-D IgG) Other infections or neural autoantibodies are also detected Summary EBV-p23 IgG measures your immune system’s response to an early antigen of Epstein-Barr Virus. Elevated levels may reflect recent infection, chronic reactivation, or persistent immune system engagement with EBV. This marker is most useful when interpreted alongside your symptoms and other immune or neurological biomarkers.